Skip to main content
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. — Investor Relations & Filings

Ticker · NERV ISIN · US6033802058 LEI · 54930017PANCHC5LYH79 US Manufacturing
Open in API
Filings indexed 589 across all filing types
Latest filing 2018-02-14 Major Shareholding Noti…
Country US United States of America
Listing US NERV

About Minerva Neurosciences, Inc.

https://www.minervaneurosciences.com/

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of product candidates for the treatment of central nervous system (CNS) diseases. The company's lead product candidate is roluperidone, which is being developed to treat the negative symptoms of schizophrenia. Minerva Neurosciences leverages its expertise in clinical development to design innovative trials with clinical endpoints aimed at demonstrating direct patient benefit.

Recent filings

Filing Released Lang Actions
SC 13G/A
Major Shareholding Notification
2018-02-14 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-02-14 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-02-13 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically details the resignation of a director and appointment of new board members, including the resignation of the Chairman and appointment of an Executive Chairman and Lead Independent Director. This matches the description of announcements related to changes in the company's board of directors or senior management. The document is not a full annual or quarterly report, nor is it an earnings release or other financial report. It is not a proxy statement or voting result announcement. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 3509 characters, which is consistent with a typical 8-K filing for management changes. Confidence is high due to clear and explicit content about director resignation and appointments.
2018-02-05 English
FORM 4 SUBMISSION
Director's Dealing
2018-02-03 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-02-01 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.